Confido Health has announced a US$10 million Series A to expand its platform, bringing its total funding to $13 million.
The round was led by Blume Ventures, with participation from new investors such as Schema Ventures, Vicus Ventures and also existing investors Together Fund, DeVC, and Medmountain Ventures, as well as strategic healthcare operators from Innovaccer, Memora Health, and a roster of Confido customers.
Confido’s system replaces the phone tree entirely.
Its voice agents answer on the first ring, authenticate the caller, check eligibility, and intelligently resolve what the patient is asking for – whether that’s a referral, refill, intake, payment, status update, or appointment booking.
When complex edge cases need human expertise, the system smoothly warm-transfers to staff, and every interaction is written back to the EHR or PMS.
In a healthcare market where less than half of patient calls get resolved on the first attempt, Confido is built to answer, resolve, and document everything in one call.
“Healthcare is at an inflection point,” said Chetan Reddy, co-founder and CEO of Confido Health.
“LaboUr shortages and rising patient demand mean practices can’t keep scaling front desks the way they used to.
“At the same time, building AI for healthcare isn’t like other industries – it requires deep empathy for both staff and patients.
“Our agents are designed to support people, not replace them, so patients get faster access and workers feel less stressed.
“That combination is what makes this moment so powerful.”
Confido’s agents are already live in paediatrics, orthopedics, GI, nephrology, dermatology, pain medicine, and more.
At Dallas Renal Group, the impact has been immediate: over 66 per cent of patients confirm appointments instantly on outbound calls, and fewer than 6 per cent need to be forwarded to staff.
On inbound calls, wait times dropped from minutes to just 15 seconds, saving staff nearly 50 hours in a single week.
“Confido has helped make access faster, smoother, and far less stressful for everyone,” said Srinivas Danda, COO of Dallas Renal Group.
The company’s roadmap reflects the same ambition.
Beyond scheduling and intake, Confido is expanding into high-value workflows like recalls, reactivation, payments, and care coordination.
With specialty playbooks, audit trails, analytics, and first-call resolution metrics, the platform is built to become the infrastructure layer for patient communication.
“We believe better access is the foundation of better care,” Reddy added.
“Phones remain the front door of healthcare, and Confido exists to make sure they open instantly, every time.
“As private equity sponsors and healthcare platforms continue to consolidate and scale specialty groups, we see Confido as the standard layer ensuring consistent, efficient, and human-like patient interactions across every clinic, regardless of size or specialty.”
